Clinical relevance of predictive physiologically based pharmacokinetic methods

Expert Opinion on Drug Discovery

Volumn 3, Issue 7, 2008, Pages 725-732

  Thomas, Simon ^a  

^a CYPROTEX DISCOVERY LTD   (United Kingdom)

Author keywords

Clinical pharmacokinetics; Mathematical modelling; Physiologically based pharmacokinetic (PBPK) modelling; Systems biology

Indexed keywords

ANTIINFECTIVE AGENT; CEFAZOLIN; CYTOCHROME P450 3A4; ERYTHROMYCIN; MACROLIDE; PLASMA PROTEIN; TRIAZOLAM; XENOBIOTIC AGENT;

ANALYTIC METHOD; ANALYTICAL ERROR; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CELL STRAIN CACO 2; CLINICAL TRIAL; COMPUTER MODEL; CONCEPTUAL FRAMEWORK; DATA ANALYSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INFORMATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TISSUE LEVEL; ENZYME ACTIVATION; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; IN VIVO STUDY; INTESTINE ABSORPTION; LIPOPHILICITY; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACOKINETICS; PHYSICOCHEMICAL MODEL; PKA; PREDICTION; PRIORITY JOURNAL; PSYCHOLOGICAL MODEL; QUANTITATIVE ANALYSIS; RELIABILITY; SIMULATION; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 48049117526     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.3.7.725     Document Type: Article

References (28)

1. Poggesi I. Predicting human pharmacokinetics from preclinical data. Curr Opin Drug Discov Devel 2004;7(1):100-11
2. Zhao YH, Le J, Abraham MH, et al. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. J Pharm Sci 2001;90(6):749-84
3. Bernareggi A, Rowland M. Physiologic modeling of cyclosporin kinetics in rat and man. J Pharmacokinet Biopharm 1991;19(1):21-50
4. Nestorov I. Whole body pharmacokinetic models. Clin Pharmacokinet 2003;42(10):883-908
5. Chiu WA, Barton HA, DeWoskin RS, et al. Evaluation of physiologically based pharmacokinetic models for use in risk assessment. J Appl Toxicol 2007;27(3):218-37
6. McMullin TS. Drugs. In: Reddy MB, Yang RSH, Clewell H Jr III, Andersen ME, editors, Physiologically based pharmacokinetic modeling: science and applications. Hoboken, New Jersey: John Wiley and Sons; Inc., 2005. p. 273-96
7. O'Brien WP. Antineoplastic agents. In: Reddy MB, Yang RSH, Clewell H Jr III, Andersen ME, editors, Physiologically based pharmacokinetic modeling: science and applications. Hoboken, New Jersey: John Wiley and Sons; Inc., 2005. p. 297-317
8. Brightman FA, Leahy DE, Searle GE, Thomas S. Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in human plasma. Drug Metab Dispos 2006;34(1):94-101
9. Ward KW, Smith BR. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug Metab Dispos 2004;32(6):603-11
10. Caldwell GW, Masucci JA, Yan Z, Hageman W. Allometric scaling of pharmacokinetic parameters in drug discovery: can human CL, Vss and t1/2 be predicted from in vivo rat data? Eur J Drug Metab Pharmacokinet 2004;29(2):133-43
11. Thomas S, Brightman F, Gill H, et al. Simulation modelling of human intestinal absorption using Caco-2 permeability and kinetic solubility data for early drug discovery. J Pharm Sci 2008 (In Press)
12. De Buck SS, Sinha VK, Fenu LA, et al. Prediction of human pharmacokinetics using physiologically based modelling: a retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 2007
13. Jones HM, Parrott N, Jorga K, Lave T. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 2006;45(5):511-42
14. Lave T, Parrott N, Grimm HP, et al. Challenges and opportunities with modelling and simulation in drug discovery and drug development. Xenobiotica 2007;37(10-11):1295-310
15. Reigner BG, Williams PE, Patel IH, et al. An evaluation of the integration of pharmacokinctic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche. Clin Pharmacokinet 1997;33(2):142-52
16. Clewell HJ, Gentry PR, Covington TR, et al. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol Sci 2004;79(2):381-93
17. Clewell RA, Merrill EA, Gearhart JM, et al. Perchlorate and radioiodide kinetics across life stages in the human: using PBPK models to predict dosimetry and thyroid inhibition and sensitive subpopulations based on developmental stage. J Toxicol Environ Health A 2007;70(5):408-28
18. Willmann S, Hohn K, Edginton A, et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn 2007;34(3):401-31
19. Kanamitsu S, Ito K, Green CE, et al. Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm Res 2000;17(4):419-26
20. Phillips JP, Antal EJ, Smith RB. A pharmacokinetic drug interaction between erythromycin and triazolam. J Clin Psychopharmacol 1986;6(5):297-9
21. Tsuji A, Nishide K, Minami H, et al. PhysiologicaUy based pharmacokinetic model for cefazolin in rabbits and its preliminary extrapolation to man. Drug Metab Dispos 1985;13(6):729-39
22. Kennedy T. Managing the drug discovery/development interface. Drug Discov Today 1997;2(10):436-44
23. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3(8):711-5
24. Westerhoff HV, Palsson BO. The evolution of molecular biology into systems biology. Nat Biotechnol 2004;22(10):1249-52
25. Revkin JH, Shear CL, Pouleur HG, et al. Biomarkers in the prevention and treatment of atherosclerosis: need, validation, and future. Pharmacol Rev 2007;59(1):40-53
26. Lappin G, Kuhnz W, Jochemsen R, et al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin Pharmacol Ther 2006;80(3):203-15
27. Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 2006;27(5):425-46
28. Pang KS. Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series). Drug Metab Dispos 2003;31(12):1507-19